Interaction of Purine and its Derivatives with A1, A2-Adenosine Receptors and Vascular Endothelial Growth Factor Receptor-1 (Vegf-R1) as a Therapeutic Alternative to Treat Cancer.

IF 1.7 Q3 PHARMACOLOGY & PHARMACY
Drug Research Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI:10.1055/a-2376-5771
Lauro Figueroa, Marcela Rosas, Magdalena Alvarez, Emilio Aguilar, Virginia Mateu, Enrique Bonilla
{"title":"Interaction of Purine and its Derivatives with A1, A2-Adenosine Receptors and Vascular Endothelial Growth Factor Receptor-1 (Vegf-R1) as a Therapeutic Alternative to Treat Cancer.","authors":"Lauro Figueroa, Marcela Rosas, Magdalena Alvarez, Emilio Aguilar, Virginia Mateu, Enrique Bonilla","doi":"10.1055/a-2376-5771","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are several studies that indicate that cancer development may be conditioned by the activation of some biological systems that involve the interaction of different biomolecules, such as adenosine and vascular endothelial growth factor. These biomolecules have been targeted of some drugs for treat of cancer; however, there is little information on the interaction of purine derivatives with adenosine and vascular endothelial growth factor receptor (VEGF-R1).</p><p><strong>Objective: </strong>The aim of this research was to determine the possible interaction of purine (1: ) and their derivatives (2-31: ) with A<sub>1</sub>, A<sub>2</sub>-adenosine receptors, and VEGF-R1.</p><p><strong>Methods: </strong>Theoretical interaction of purine and their derivatives with A<sub>1</sub>, A<sub>2</sub>-adenosine receptors and VEGF-R1 was carried out using the 5uen, 5mzj and 3hng proteins as theoretical tools. Besides, adenosine, cgs-15943, rolofylline, cvt-124, wrc-0571, luf-5834, cvt-6883, AZD-4635, cabozantinib, pazopanib, regorafenib, and sorafenib drugs were used as controls.</p><p><strong>Results: </strong>The results showed differences in the number of aminoacid residues involved in the interaction of purine and their derivatives with 5uen, 5mzj and 3hng proteins compared with the controls. Besides, the inhibition constants (Ki) values for purine and their derivatives 5: , 9: , 10: , 14: , 15: , 16: , and 20: were lower compared with the controls CONCLUSIONS: Theoretical data suggest that purine and their derivatives 5: , 9: , 10: , 14: , 15: , 16: , and 20: could produce changes in cancer cell growth through inhibition of A<sub>1</sub>, A<sub>2</sub>-adenosine receptors and VEGFR-1 inhibition. These data indicate that these purine derivatives could be a therapeutic alternative to treat some types of cancer.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2376-5771","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There are several studies that indicate that cancer development may be conditioned by the activation of some biological systems that involve the interaction of different biomolecules, such as adenosine and vascular endothelial growth factor. These biomolecules have been targeted of some drugs for treat of cancer; however, there is little information on the interaction of purine derivatives with adenosine and vascular endothelial growth factor receptor (VEGF-R1).

Objective: The aim of this research was to determine the possible interaction of purine (1: ) and their derivatives (2-31: ) with A1, A2-adenosine receptors, and VEGF-R1.

Methods: Theoretical interaction of purine and their derivatives with A1, A2-adenosine receptors and VEGF-R1 was carried out using the 5uen, 5mzj and 3hng proteins as theoretical tools. Besides, adenosine, cgs-15943, rolofylline, cvt-124, wrc-0571, luf-5834, cvt-6883, AZD-4635, cabozantinib, pazopanib, regorafenib, and sorafenib drugs were used as controls.

Results: The results showed differences in the number of aminoacid residues involved in the interaction of purine and their derivatives with 5uen, 5mzj and 3hng proteins compared with the controls. Besides, the inhibition constants (Ki) values for purine and their derivatives 5: , 9: , 10: , 14: , 15: , 16: , and 20: were lower compared with the controls CONCLUSIONS: Theoretical data suggest that purine and their derivatives 5: , 9: , 10: , 14: , 15: , 16: , and 20: could produce changes in cancer cell growth through inhibition of A1, A2-adenosine receptors and VEGFR-1 inhibition. These data indicate that these purine derivatives could be a therapeutic alternative to treat some types of cancer.

嘌呤及其衍生物与 A1、A2-腺苷受体和血管内皮生长因子受体-1 (Vegf-R1) 的相互作用可作为治疗癌症的一种替代疗法。
背景:一些研究表明,癌症的发生可能受某些生物系统激活的制约,这些系统涉及不同生物分子的相互作用,如腺苷和血管内皮生长因子。这些生物分子已成为一些治疗癌症药物的靶点;然而,有关嘌呤衍生物与腺苷和血管内皮生长因子受体(VEGF-R1)相互作用的信息却很少:本研究旨在确定嘌呤(1: )及其衍生物(2-31: )与 A1、A2-腺苷受体和血管内皮生长因子-R1 之间可能存在的相互作用:以 5uen、5mzj 和 3hng 蛋白为理论工具,研究了嘌呤及其衍生物与 A1、A2-腺苷受体和 VEGF-R1 的理论相互作用。此外,还使用腺苷、cgs-15943、rolofylline、cvt-124、wrc-0571、luf-5834、cvt-6883、AZD-4635、卡博赞替尼、帕唑帕尼、瑞戈非尼和索拉非尼等药物作为对照:结果表明,与对照组相比,嘌呤及其衍生物与 5uen、5mzj 和 3hng 蛋白相互作用的氨基酸残基数量存在差异。此外,与对照组相比,嘌呤及其衍生物 5: 、9: 、10: 、14: 、15: 、16: 和 20: 的抑制常数(Ki)值较低:理论数据表明,嘌呤及其衍生物 5:、9:、10:、14:、15:、16:和 20:可通过抑制 A1、A2-腺苷受体和 VEGFR-1 抑制剂来改变癌细胞的生长。这些数据表明,这些嘌呤衍生物可以成为治疗某些类型癌症的替代疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Research
Drug Research PHARMACOLOGY & PHARMACY-
CiteScore
3.50
自引率
0.00%
发文量
67
期刊介绍: Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信